MYOCET

This brand name is authorized in Austria, Cyprus, Estonia, Spain, Finland, Ireland, Lithuania, Netherlands, Poland, Romania

Active ingredients

The drug MYOCET contains one active pharmaceutical ingredient (API):

1 Doxorubicin
UNII 82F2G7BL4E - DOXORUBICIN HYDROCHLORIDE

Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects.

Read about Doxorubicin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01DB01 Doxorubicin L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1212398, 1598003
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 00141001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 003099
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1029920, 1065432
Country: NL Z-Index G-Standaard, PRK Identifier(s): 77984
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100133608
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W69351001

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.